Abstract
Our initial studies on renal cyclooxygenase (COX)-2 expression and activity addressed the critical role of angiotensin II (Ang II) in increasing tumor necrosis factor alpha (TNF) that eventuated in expression of COX-2 in the medullary thick ascending limb (mTAL) of the nephron. COX-2 supplanted the dominant oxygenase, the cytochrome P450 (CYP) enzyme, w- hydroxylase, that synthesized 20-hydroxyeicosatetraenoic acid (20-HETE). These findings served as the basis for additional studies on: 1) the role of glucocorticoids in regulating COX-2 expression and activity in the mTAL; and 2) the utilization of the same signaling pathways in response to stimulation of the mTAL calcium receptor (CaR). These studies of mTAL COX-2 expression which are addressed in the first part of this chapter are followed by explorations of the expression of COX-2 in preglomerular microvessels (PGMV) and the relationship of COX-2 to 20- HETE, the principal eicosanoid of PGMV. The third and last component of this chapter explores the signaling events, focusing on COX-2, which are set in motion by diabetes.
Keywords: calcium receptor (car), cyclooxygenase (cox)-2, diabetes, hypertension, prostaglandin e2 (pge2), thick ascending limb (tal), tumor necrosis factor alpha (tnf), 20-hydroxyeicosatetraenoic acid (20-hete)
Current Pharmaceutical Design
Title: Renal COX-2, Cytokines and 20-HETE: Tubular and Vascular Mechanisms
Volume: 10 Issue: 6
Author(s): Nicholas R. Ferreri, John C. McGiff, Mairead A. Carroll and John Quilley
Affiliation:
Keywords: calcium receptor (car), cyclooxygenase (cox)-2, diabetes, hypertension, prostaglandin e2 (pge2), thick ascending limb (tal), tumor necrosis factor alpha (tnf), 20-hydroxyeicosatetraenoic acid (20-hete)
Abstract: Our initial studies on renal cyclooxygenase (COX)-2 expression and activity addressed the critical role of angiotensin II (Ang II) in increasing tumor necrosis factor alpha (TNF) that eventuated in expression of COX-2 in the medullary thick ascending limb (mTAL) of the nephron. COX-2 supplanted the dominant oxygenase, the cytochrome P450 (CYP) enzyme, w- hydroxylase, that synthesized 20-hydroxyeicosatetraenoic acid (20-HETE). These findings served as the basis for additional studies on: 1) the role of glucocorticoids in regulating COX-2 expression and activity in the mTAL; and 2) the utilization of the same signaling pathways in response to stimulation of the mTAL calcium receptor (CaR). These studies of mTAL COX-2 expression which are addressed in the first part of this chapter are followed by explorations of the expression of COX-2 in preglomerular microvessels (PGMV) and the relationship of COX-2 to 20- HETE, the principal eicosanoid of PGMV. The third and last component of this chapter explores the signaling events, focusing on COX-2, which are set in motion by diabetes.
Export Options
About this article
Cite this article as:
Ferreri R. Nicholas, McGiff C. John, Carroll A. Mairead and Quilley John, Renal COX-2, Cytokines and 20-HETE: Tubular and Vascular Mechanisms, Current Pharmaceutical Design 2004; 10 (6) . https://dx.doi.org/10.2174/1381612043453063
DOI https://dx.doi.org/10.2174/1381612043453063 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Commentary: Perivascular Fat and Improved Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Novel Patented Src Kinase Inhibitor
Current Medicinal Chemistry Subject Index To Volume 6
Anti-Cancer Agents in Medicinal Chemistry Phenotypic Screening for Pharmaceuticals Using Tissue Constructs
Current Pharmaceutical Biotechnology Applications of Umbilical Cord Derived Mesenchymal Stem Cells in Autoimmune and Immunological Disorders: From Literature to Clinical Practice
Current Stem Cell Research & Therapy Inflammation, Adipocytokines, and Atherosclerosis in the Metabolic Syndrome
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Deletion of Endoplasmic Reticulum Stress-Induced CHOP Protects Microvasculature Post-Spinal Cord Injury
Current Neurovascular Research Structural Activity Relationship and Importance of Benzothiazole Derivatives in Medicinal Chemistry: A Comprehensive Review
Mini-Reviews in Organic Chemistry Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) Tyrosine Kinases and Inflammatory Signalling
Current Molecular Medicine Inflammatory Mechanisms in Myocardial Infarction
Current Drug Targets - Inflammation & Allergy Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) The Role of AGEs and AGE Inhibitors in Diabetic Cardiovascular Disease
Current Drug Targets Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Toxin-Labeled Monoclonal Antibodies
Current Pharmaceutical Biotechnology Biologically Active Natural Products of the Genus Callicarpa
Current Bioactive Compounds Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets The Updated Role of Oxidative Stress in Subarachnoid Hemorrhage
Current Drug Delivery Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery